H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1639, 2015.

R. S. Herbst, P. Baas, and D. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-1550, 2016.

A. Rittmeyer, F. Barlesi, and D. Waterkamp, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-265, 2017.

M. Reck, D. Rodríguez-abreu, and A. G. Robinson, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1833, 2016.

L. Gandhi, D. Rodríguez-abreu, and S. Gadgeel, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, issue.22, pp.2078-2092, 2018.

M. A. Socinski, R. M. Jotte, and F. Cappuzzo, Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.378, issue.24, pp.2288-2301, 2018.

S. J. Antonia, A. Villegas, and D. Daniel, Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.379, issue.24, pp.2342-2350, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02284390

P. M. Forde, J. E. Chaft, and K. N. Smith, Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N Engl J Med, vol.378, issue.21, pp.1976-1986, 2018.

L. Horn, A. S. Mansfield, and A. Szcz?sna, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med, vol.379, issue.23, pp.2220-2229, 2018.

G. Popinat, S. Cousse, and L. Goldfarb, Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV nonsmall cell lung cancer treated by nivolumab, Oncoimmunology, vol.8, issue.5, p.1580128, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02342305

P. H. Aussedat and P. Tomasini,

F. Barlesi and L. Greillier, Clinical predictive factors for 3-months disease control with immune checkpoint inhibitors in patients with non-small cell lung cancer

T. F. Nishijima, H. B. Muss, S. S. Shachar, and S. J. Moschos, Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev, vol.45, pp.30-37, 2016.

V. Gopalakrishnan, B. A. Helmink, C. N. Spencer, A. Reuben, and J. A. Wargo, The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell, vol.33, issue.4, pp.570-580, 2018.

S. Huo, L. Liu, J. Liu, Q. Li, and J. Wang, Modulation of cancer immunotherapy efficacy by gut microbiota, Discov Med, vol.27, issue.147, pp.93-100, 2019.

M. Gooden, G. H. Bock, . De, N. Leffers, T. Daemen et al., The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis, Br J Cancer, vol.105, issue.1, pp.93-103, 2011.

F. Balkwill and A. Mantovani, Inflammation and cancer: back to Virchow?, Lancet Lond Engl, vol.357, issue.9255, pp.539-545, 2001.

A. M. Hopkins, A. Rowland, and G. Kichenadasse, Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers, Br J Cancer, vol.117, issue.7, pp.913-920, 2017.

M. J. Proctor, D. C. Mcmillan, D. S. Morrison, C. D. Fletcher, P. G. Horgan et al., A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer, Br J Cancer, vol.107, issue.4, pp.695-699, 2012.

P. F. Ferrucci, P. A. Ascierto, and J. Pigozzo, Baseline neutrophils and derived neutrophil-tolymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.4, pp.732-738, 2016.

C. I. Diakos, D. Tu, and V. Gebski, Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies, Ann Oncol, issue.suppl_6, p.27, 2016.

X. Gu, S. Sun, and X. Gao, Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients, vol.6, 2016.

L. Mezquita, E. Auclin, and R. Ferrara, Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer, JAMA Oncol, vol.4, issue.3, pp.351-357, 2018.

A. Pavan, L. Calvetti, D. Maso, and A. , Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors, The Oncologist, 2019.

S. Benzekry, E. Pasquier, and D. Barbolosi, Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Semin Cancer Biol, vol.35, pp.53-61, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01195547

C. Faivre, R. El-cheikh, D. Barbolosi, and F. Barlesi, Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients, Br J Cancer, vol.116, issue.3, pp.344-348, 2017.

D. Imbs, E. Cheikh, R. Boyer, and A. , Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma, CPT Pharmacomet Syst Pharmacol, vol.7, issue.1, pp.42-50, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01624423

F. Barlesi, D. Imbs, and P. Tomasini, Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients, Oncotarget, vol.8, issue.29, pp.47161-47166, 2017.

R. Serre, S. Benzekry, and L. Padovani, Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy, Cancer Res, vol.76, issue.17, pp.4931-4940, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01336779

R. Serre, F. Barlesi, X. Muracciole, and D. Barbolosi, Immunologically effective dose: a practical model for immuno-radiotherapy, Oncotarget, vol.9, issue.61, pp.31812-31819, 2018.

N. Branger, X. Muraciolle, and C. Bastide, Modélisation mathématique de la cinétique du PSA appliquée à la détection précoce du cancer de la prostate, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, vol.24, issue.13, p.787, 2014.

E. A. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, issue.2, pp.228-247, 2009.

, The R Project for Statistical Computing, 2019.

M. Kuhn, Building Predictive Models in R Using the caret Package, J Stat Softw, vol.28, issue.1, pp.1-26, 2008.

D. R. Cox, Regression Models and Life-Tables, J R Stat Soc Ser B Methodol, vol.34, issue.2, pp.187-202, 1972.

F. E. Harrell, K. L. Lee, and D. B. Mark, Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors, Stat Med, vol.15, issue.4, pp.361-387, 1996.

B. Melosky, Q. Chu, and R. A. Juergens, Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC, Cancer Treat Rev, vol.65, pp.65-77, 2018.

Y. Liu, Z. Dong, and T. Jiang, Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma, Clin Lung Cancer, vol.19, issue.4, pp.421-430, 2018.

D. J. Boffa, R. P. Graf, and M. C. Salazar, Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.26, issue.7, pp.1139-1145, 2017.

L. Berland, S. Heeke, and O. Humbert, Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors, J Thorac Dis, vol.11, issue.1, pp.71-80, 2018.

L. B. Alexandrov, S. Nik-zainal, and D. C. Wedge, Signatures of mutational processes in human cancer, Nature, vol.500, issue.7463, pp.415-421, 2013.

M. S. Lawrence, P. Stojanov, and P. Polak, Mutational heterogeneity in cancer and the search for new cancer genes, Nature, vol.499, issue.7457, pp.214-218, 2013.

H. Rizvi, F. Sanchez-vega, and K. La, Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, issue.7, pp.633-641, 2018.

D. R. Gandara, M. Kowanetz, and T. Mok, 1295OBlood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK), Ann Oncol, vol.28, issue.suppl_5, 2019.

A. Jeanson, P. Tomasini, and M. Souquet-bressand, Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC), J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.14, issue.6, pp.1095-1101, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02104417

J. Mazières, A. Drilon, and A. Lusque, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol Off J Eur Soc Med Oncol, 2019.

F. Skoulidis, L. A. Byers, and L. Diao, Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities, Cancer Discov, vol.5, issue.8, pp.860-877, 2015.

F. Skoulidis, M. E. Goldberg, and D. M. Greenawalt, STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma, Cancer Discov, vol.8, issue.7, pp.822-835, 2018.

L. Claret, J. Y. Jin, and C. Ferté, A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics, Clin Cancer Res Off J Am Assoc Cancer Res, vol.24, issue.14, pp.3292-3298, 2018.

N. Guibert, J. Mazieres, and M. Delaunay, Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma, Oncotarget, vol.8, issue.23, pp.38056-38060, 2017.

J. Brahmer, K. L. Reckamp, and P. Baas, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.2, pp.123-135, 2015.

V. Mayer-schönberger and E. Ingelsson, Big Data and medicine: a big deal, J Intern Med, vol.283, issue.5, pp.418-429, 2018.

M. Montazeri, M. Montazeri, M. Montazeri, and A. Beigzadeh, Machine learning models in breast cancer survival prediction. Technol Health Care Off J, Eur Soc Eng Med, vol.24, issue.1, pp.31-42, 2016.

J. A. Bartholomai and H. B. Frieboes, Lung Cancer Survival Prediction via Machine Learning Regression, Classification, and Statistical Techniques, Proc IEEE Int Symp Signal Process Inf Technol IEEE Int Symp Signal Process Inf Technol, vol.2018, pp.632-637, 2018.

R. Sun, E. J. Limkin, and M. Vakalopoulou, A radiomics approach to assess tumourinfiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, vol.19, issue.9, pp.1180-1191, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01958243

H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1639, 2015.

R. S. Herbst, P. Baas, and D. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-1550, 2016.

A. Rittmeyer, F. Barlesi, and D. Waterkamp, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-265, 2017.

M. Reck, D. Rodríguez-abreu, and A. G. Robinson, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1833, 2016.

L. Gandhi, D. Rodríguez-abreu, and S. Gadgeel, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, issue.22, pp.2078-2092, 2018.

M. A. Socinski, R. M. Jotte, and F. Cappuzzo, Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.378, issue.24, pp.2288-2301, 2018.

S. J. Antonia, A. Villegas, and D. Daniel, Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.379, issue.24, pp.2342-2350, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02284390

P. M. Forde, J. E. Chaft, and K. N. Smith, Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N Engl J Med, vol.378, issue.21, pp.1976-1986, 2018.

L. Horn, A. S. Mansfield, and A. Szcz?sna, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med, vol.379, issue.23, pp.2220-2229, 2018.

G. Popinat, S. Cousse, and L. Goldfarb, Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV nonsmall cell lung cancer treated by nivolumab, Oncoimmunology, vol.8, issue.5, p.1580128, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02342305

P. H. Aussedat and P. Tomasini,

F. Barlesi and L. Greillier, Clinical predictive factors for 3-months disease control with immune checkpoint inhibitors in patients with non-small cell lung cancer

T. F. Nishijima, H. B. Muss, S. S. Shachar, and S. J. Moschos, Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev, vol.45, pp.30-37, 2016.

V. Gopalakrishnan, B. A. Helmink, C. N. Spencer, A. Reuben, and J. A. Wargo, The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell, vol.33, issue.4, pp.570-580, 2018.

S. Huo, L. Liu, J. Liu, Q. Li, and J. Wang, Modulation of cancer immunotherapy efficacy by gut microbiota, Discov Med, vol.27, issue.147, pp.93-100, 2019.

M. Gooden, G. H. Bock, . De, N. Leffers, T. Daemen et al., The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis, Br J Cancer, vol.105, issue.1, pp.93-103, 2011.

F. Balkwill and A. Mantovani, Inflammation and cancer: back to Virchow?, Lancet Lond Engl, vol.357, issue.9255, pp.539-545, 2001.

A. M. Hopkins, A. Rowland, and G. Kichenadasse, Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers, Br J Cancer, vol.117, issue.7, pp.913-920, 2017.

M. J. Proctor, D. C. Mcmillan, D. S. Morrison, C. D. Fletcher, P. G. Horgan et al., A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer, Br J Cancer, vol.107, issue.4, pp.695-699, 2012.

P. F. Ferrucci, P. A. Ascierto, and J. Pigozzo, Baseline neutrophils and derived neutrophilto-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.4, pp.732-738, 2016.

C. I. Diakos, D. Tu, and V. Gebski, Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies, Ann Oncol, vol.27, issue.suppl_6, 2019.

X. Gu, S. Sun, and X. Gao, Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients, vol.6, 2016.

L. Mezquita, E. Auclin, and R. Ferrara, Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer, JAMA Oncol, vol.4, issue.3, pp.351-357, 2018.

A. Pavan, L. Calvetti, D. Maso, and A. , Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors, The Oncologist, 2019.

S. Benzekry, E. Pasquier, and D. Barbolosi, Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Semin Cancer Biol, vol.35, pp.53-61, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01195547

C. Faivre, R. El-cheikh, D. Barbolosi, and F. Barlesi, Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients, Br J Cancer, vol.116, issue.3, pp.344-348, 2017.

D. Imbs, E. Cheikh, R. Boyer, and A. , Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma, CPT Pharmacomet Syst Pharmacol, vol.7, issue.1, pp.42-50, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01624423

F. Barlesi, D. Imbs, and P. Tomasini, Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients, Oncotarget, vol.8, issue.29, pp.47161-47166, 2017.

R. Serre, S. Benzekry, and L. Padovani, Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy, Cancer Res, vol.76, issue.17, pp.4931-4940, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01336779

R. Serre, F. Barlesi, X. Muracciole, and D. Barbolosi, Immunologically effective dose: a practical model for immuno-radiotherapy, Oncotarget, vol.9, issue.61, pp.31812-31819, 2018.

N. Branger, X. Muraciolle, and C. Bastide, Modélisation mathématique de la cinétique du PSA appliquée à la détection précoce du cancer de la prostate, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, vol.24, issue.13, p.787, 2014.

E. A. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 32. R: The R Project for Statistical Computing, vol.45, pp.228-247, 2009.

M. Kuhn, Building Predictive Models in R Using the caret Package, J Stat Softw, vol.28, issue.1, pp.1-26, 2008.

D. R. Cox, Regression Models and Life-Tables, J R Stat Soc Ser B Methodol, vol.34, issue.2, pp.187-202, 1972.

F. E. Harrell, K. L. Lee, and D. B. Mark, Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors, Stat Med, vol.15, issue.4, pp.361-387, 1996.

B. Melosky, Q. Chu, and R. A. Juergens, Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC, Cancer Treat Rev, vol.65, pp.65-77, 2018.

Y. Liu, Z. Dong, and T. Jiang, Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma, Clin Lung Cancer, vol.19, issue.4, pp.421-430, 2018.

D. J. Boffa, R. P. Graf, and M. C. Salazar, Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.26, issue.7, pp.1139-1145, 2017.

L. Berland, S. Heeke, and O. Humbert, Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors, J Thorac Dis, vol.11, issue.1, pp.71-80, 2018.

L. B. Alexandrov, S. Nik-zainal, and D. C. Wedge, Signatures of mutational processes in human cancer, Nature, vol.500, issue.7463, pp.415-421, 2013.

M. S. Lawrence, P. Stojanov, and P. Polak, Mutational heterogeneity in cancer and the search for new cancer genes, Nature, vol.499, issue.7457, pp.214-218, 2013.

H. Rizvi, F. Sanchez-vega, and K. La, Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, issue.7, pp.633-641, 2018.

D. R. Gandara, M. Kowanetz, and T. Mok, 1295OBlood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK), Ann Oncol, vol.28, issue.suppl_5, 2019.

A. Jeanson, P. Tomasini, and M. Souquet-bressand, Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC), J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.14, issue.6, pp.1095-1101, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02104417

J. Mazières, A. Drilon, and A. Lusque, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol Off J Eur Soc Med Oncol, 2019.

F. Skoulidis, L. A. Byers, and L. Diao, Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities, Cancer Discov, vol.5, issue.8, pp.860-877, 2015.

F. Skoulidis, M. E. Goldberg, and D. M. Greenawalt, STK11/LKB1 Mutations, p.1

, Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma, Cancer Discov, vol.8, issue.7, pp.822-835, 2018.

L. Claret, J. Y. Jin, and C. Ferté, A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics, Clin Cancer Res Off J Am Assoc Cancer Res, vol.24, issue.14, pp.3292-3298, 2018.

N. Guibert, J. Mazieres, and M. Delaunay, Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma, Oncotarget, vol.8, issue.23, pp.38056-38060, 2017.

J. Brahmer, K. L. Reckamp, and P. Baas, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.2, pp.123-135, 2015.

V. Mayer-schönberger and E. Ingelsson, Big Data and medicine: a big deal, J Intern Med, vol.283, issue.5, pp.418-429, 2018.

M. Montazeri, M. Montazeri, M. Montazeri, and A. Beigzadeh, Machine learning models in breast cancer survival prediction. Technol Health Care Off J, Eur Soc Eng Med, vol.24, issue.1, pp.31-42, 2016.

J. A. Bartholomai and H. B. Frieboes, Lung Cancer Survival Prediction via Machine Learning Regression, Classification, and Statistical Techniques, Proc IEEE Int Symp Signal Process Inf Technol IEEE Int Symp Signal Process Inf Technol, vol.2018, pp.632-637, 2018.

R. Sun, E. J. Limkin, and M. Vakalopoulou, A radiomics approach to assess tumourinfiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, vol.19, issue.9, pp.1180-1191, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01958243